RxDoctor Payments DataLook up a doctor →

Edward Kim

Medical Oncology · Charlotte, NCNPI 1972688984

Payments from drug & device makers

$1,659,505in general payments, 2019–2025

Across 264 payments — averaging $6286.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$815K
  • Genentech, Inc.$212K
  • AstraZeneca$208K
  • Astrazeneca UK Limited$191K
  • Incyte Corporation$41K
  • Regeneron$35K
  • plus $156K from 30 others
$22,735in research payments, 2019–2025

Across 11 payments — averaging $2066.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$6K
  • Celltrion, Inc.$5K
  • Bristol Myers Squibb$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Genentech, Inc.$2K
  • Novartis Pharma AG$2K
  • plus $2K from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,659,505 in reported general payments places this provider in the 85th percentile of 170 medical oncology providers in North Carolina.

See all medical oncology providers in North Carolina

Other medical oncology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →